Efficacy of soybean-based vaccines using a model antigen

使用模型抗原的大豆疫苗的功效

基本信息

项目摘要

DESCRIPTION (provided by applicant): Vaccines that stimulate mucosal immune responses of the gastrointestinal tract would be advantageous since such formulations would provide immunity at the site of pathogen entry. Edible vaccines have received much attention since, in theory, they represent a source of vaccine that would stimulate immune responses of the gastrointestinal tract, be cost-effective to produce, safe to administer, and a highly stable form for shipment throughout the world. Unfortunately, there are many practical problems that remain when trying to reduce such potential into reality. Studies to be conducted here will directly address some of the most important challenges that face this technology for developing edible subunit vaccines in soybeans which could be applied to the formulation of novel human gastrointestinal vaccines. We propose the use of a model antigen, E. coli FanC, so that definitive questions can be addressed regarding the protective nature of the humoral and cell mediated gastrointestinal response induced when this edible vaccine is coupled with an oral adjuvant. Expression of the model antigen, E. coli FanC, in transgenic soybeans will be used to provide practical information regarding the utility of edible subunit vaccines. Following oral immunization with FanC expressed in transgenic soybeans coupled with an oral adjuvant, the humoral and cellular immune response will be defined at mucosal and systemic sites. In addition, the ability of this vaccine formulation to protect mice against a challenge with enterotoxigenic E. coli will also be determined. Finally, novel formulations of this edible vaccine will be investigated for their potential to stimulate gastrointestinal immunity. Despite the promise of plant based vaccines as a low cost method for stimulating gastrointestinal immunity, significant questions still remain about the feasibility of developing such methods for immunizing humans. The present proposal focuses on the practicality of using edible subunit vaccines for oral immunization.
描述(由申请人提供):刺激胃肠道粘膜免疫应答的疫苗将是有利的,因为这种制剂将在病原体进入部位提供免疫力。可食用疫苗受到了广泛关注,因为在理论上,它们代表了一种疫苗来源,该疫苗将刺激胃肠道的免疫应答,生产成本低,给药安全,并且是一种高度稳定的形式,可在世界各地运输。不幸的是,在试图将这种潜力变为现实时,仍然存在许多实际问题。在此进行的研究将直接解决该技术在大豆中开发可食用亚单位疫苗所面临的一些最重要的挑战,这些疫苗可应用于新型人类胃肠道疫苗的配制。我们建议使用模型抗原,E。大肠杆菌FanC,使明确的问题,可以解决有关的体液和细胞介导的胃肠道反应时,这种可食用疫苗与口服佐剂耦合诱导的保护性。 模型抗原E.大肠杆菌FanC,在转基因大豆将被用来提供实用的信息,关于实用的可食用亚单位疫苗。用转基因大豆中表达的FanC与口服佐剂联用口服免疫后,将在粘膜和全身部位确定体液和细胞免疫应答。此外,该疫苗制剂保护小鼠免受肠毒素E.大肠杆菌也将被确定。最后,将研究这种可食用疫苗的新配方是否具有刺激胃肠道免疫的潜力。尽管基于植物的疫苗有望作为刺激胃肠道免疫的低成本方法,但关于开发用于免疫人类的这种方法的可行性仍然存在重大问题。目前的建议集中在使用可食用亚单位疫苗口服免疫的实用性。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KENNETH J PILLER其他文献

KENNETH J PILLER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KENNETH J PILLER', 18)}}的其他基金

Oral autoantigen therapy for the treatment of Multiple Sclerosis
口服自身抗原疗法治疗多发性硬化症
  • 批准号:
    10157209
  • 财政年份:
    2021
  • 资助金额:
    $ 25.27万
  • 项目类别:
Oral autoantigen therapy for the treatment of Multiple Sclerosis
口服自身抗原疗法治疗多发性硬化症
  • 批准号:
    10331867
  • 财政年份:
    2021
  • 资助金额:
    $ 25.27万
  • 项目类别:
Platform for practical delivery of oral autoantigens as co-therapies for neurological disease
口腔自身抗原作为神经系统疾病联合疗法的实际递送平台
  • 批准号:
    9341398
  • 财政年份:
    2016
  • 资助金额:
    $ 25.27万
  • 项目类别:
Improved diagnostic and monitoring assays for thyroid cancer
改进甲状腺癌的诊断和监测分析
  • 批准号:
    7907500
  • 财政年份:
    2010
  • 资助金额:
    $ 25.27万
  • 项目类别:
Improved diagnostic and monitoring assays for thyroid cancer
改进甲状腺癌的诊断和监测分析
  • 批准号:
    8591270
  • 财政年份:
    2010
  • 资助金额:
    $ 25.27万
  • 项目类别:
Improved diagnostic and monitoring assays for thyroid cancer
改进甲状腺癌的诊断和监测分析
  • 批准号:
    8885710
  • 财政年份:
    2010
  • 资助金额:
    $ 25.27万
  • 项目类别:
Improved diagnostic and monitoring assays for thyroid cancer
改进甲状腺癌的诊断和监测分析
  • 批准号:
    8692671
  • 财政年份:
    2010
  • 资助金额:
    $ 25.27万
  • 项目类别:
Novel therapy for treating Multiple Sclerosis
治疗多发性硬化症的新疗法
  • 批准号:
    7668842
  • 财政年份:
    2009
  • 资助金额:
    $ 25.27万
  • 项目类别:
A Novel Therapy for Staphyloccocal Enterotoxin B poisoning
治疗葡萄球菌肠毒素 B 中毒的新疗法
  • 批准号:
    7271825
  • 财政年份:
    2007
  • 资助金额:
    $ 25.27万
  • 项目类别:
Efficacy of soybean-based vaccines using a model antigen
使用模型抗原的大豆疫苗的功效
  • 批准号:
    6926625
  • 财政年份:
    2005
  • 资助金额:
    $ 25.27万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 25.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了